ArticleFrontiers in pharmacology2026
Targeting UAP1 with rabeprazole: a novel repurposed therapeutic strategy for multiple myeloma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite significant advancements in proteasome inhibitors and immunomodulatory drugs, multiple myeloma (MM) remains largely incurable due to persistent drug resistance and frequent relapse, highlighting an urgent need for novel therapeutic targets. Methods: We analyzed Multiple Myeloma Research Foundation and GEO datasets to identify genes associated with disease progression, prioritizing UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) for functional validation. The impact of UAP1 on MM cell growth was evaluated through both Results: UAP1 was found to be overexpressed in MM patients and positively correlated with disease severity. UAP1 knockdown significantly suppressed MM cell proliferation, and promoted apoptosis. Mechanistically, integrated multi-omics analysis revealed that this growth inhibition was driven by the dysregulation of protein biosynthesis, degradation, and amino acid metabolism. Virtual screening identified Rabeprazole (RAB) as a potent expression suppressor candidate. RAB effectively inhibited MM cell growth by downregulating UAP1 expression and exhibited synergistic anti-myeloma effects when combined with the proteasome inhibitor bortezomib. Knockdown and overexpression experiments confirmed that UAP1 is a functional target of RAB. Conclusion: Our findings establish UAP1 as a critical driver of MM progression and a promising therapeutic target. Genetic or pharmacological inhibition of UAP1 expression
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.